Entries by Katja Buhrer

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit

San Francisco, California (February 18, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch Animal Health Summit on February 24 in New York City. Dr. Richard Chin, Chief Executive Officer, will present and be available for one-on-one […]

Kindred Biosciences Announces Half-Life Extension Technology for Canine Antibodies

Positive results from canine pharmacokinetic study demonstrate up to three-fold increase in antibody half-life. Longer half-lives have the potential to reduce dosing frequency, lower doses, and/or reduce cost of goods sold. Technology expected to lead to multiple best-in-class products. San Francisco, California (January 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company […]

Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in Dogs

San Francisco, California (December 16, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results from its randomized, placebo-controlled laboratory pilot study of KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 receptor (IL-4R), for the treatment of atopic dermatitis in dogs. […]

Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss

Mirataz is the first and only medication approved in the European Union to treat cats experiencing poor appetite and weight loss resulting from chronic medical conditions. San Francisco, California (December 12, 2019) – Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the […]

Kindred Biosciences Receives FDA Approval of Zimeta™ (dipyrone injection) for the Control of Pyrexia in Horses

San Francisco, California (November 25, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has approved Zimeta™ (dipyrone injection) for the control of pyrexia in horses. Pyrexia, or fever, is associated with […]

Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare Conference

San Francisco, California (November 14, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21. Dr. Richard Chin, Chief Executive Officer, will present and be available […]

Kindred Biosciences Announces Third Quarter 2019 Financial Results

San Francisco, California (November 12, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2019 and provided updates on its programs. For the third quarter 2019, KindredBio reported net product revenues of $1.1 million and a net loss […]